Target identification in small cell lung cancer via integrated phenotypic screening and activity-based protein profiling

Molecular Cancer Therapeutics

Volumn 15, Issue 2, 2016, Pages 334-342

  Li, Jiannong ^a   Fang, Bin ^a   Kinose, Fumi ^a   Bai, Yun ^a   Kim, Jae Young ^a   Chen, Yian A ^a   Rix, Uwe ^a   Koomen, John M ^a   Haura, Eric B ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 3 [3 (5 MORPHOLINOMETHYL 1H BENZIMIDAZOL 2 YL) 1H PYRAZOL 4 YL]UREA; ADENOSINE TRIPHOSPHATE; ALISERTIB; ANTINEOPLASTIC AGENT; AURORA B KINASE; BARASERTIB; BIOTIN DERIVATIVE; BX 795; DANUSERTIB; DESTHIOBIOTIN; ENMD 2076; MYC PROTEIN; NOCODAZOLE; POLO LIKE KINASE 1; PROTEIN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE INHIBITOR; SNS 314; TAK 901; TANK BINDING KINASE 1; TOZASERTIB; UNCLASSIFIED DRUG; BIOTIN; MOLECULAR LIBRARY; MYC PROTEIN, HUMAN; TUMOR MARKER;

ACTIVITY BASED PROTEIN PROFILING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SCREENING; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MOLECULAR PROBE; NUCLEIC ACID AMPLIFICATION; PEPTIDE LIBRARY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; SIGNAL TRANSDUCTION; SMALL CELL LUNG CANCER; ANALOGS AND DERIVATIVES; CELL SURVIVAL; DRUG EFFECTS; GENE AMPLIFICATION; GENETICS; ISOLATION AND PURIFICATION; LUNG TUMOR; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; TUMOR CELL LINE;

APOPTOSIS; BIOMARKERS, TUMOR; BIOTIN; CELL LINE, TUMOR; CELL SURVIVAL; GENE AMPLIFICATION; HUMANS; LUNG NEOPLASMS; PHENOTYPE; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; SMALL CELL LUNG CARCINOMA; SMALL MOLECULE LIBRARIES;

EID: 84960449289     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-15-0444     Document Type: Article

References (31)

1. Anastassiadis T, Deacon SW, Devarajan K, Ma H, Peterson JR. Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity. Nat Biotechnol 2011;29:1039-45.
2. Kaelin WG Jr. Molecular biology. Use and abuse of RNAi to study mammalian gene function. Science 2012;337:421-2.
3. Rix U, Superti-Furga G. Target profiling of small molecules by chemical proteomics. Nat Chem Biol 2009;5:616-24.
4. Xiao Y, Guo L, Wang Y. A targeted quantitative proteomics strategy for global kinome profiling of cancer cells and tissues. Mol Cell Proteom 2014;13:1065-75.
5. Worboys JD, Sinclair J, Yuan Y, Jorgensen C. Systematic evaluation of quantotypic peptides for targeted analysis of the human kinome. Nat Methods 2014;11:1041-4.
6. Patricelli MP, Nomanbhoy TK, Wu J, Brown H, Zhou D, Zhang J, et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem Biol 2011;18:699-710.
7. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
8. Li J, Rix U, Fang B, Bai Y, Edwards A, Colinge J, et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat Chem Biol 2010;6:291-9.
9. Cox J, Mann M. MaxQuant enables high peptide identification rates, individualized p. p. b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 2008;26:1367-72.
10. Li J, Bennett K, Stukalov A, Fang B, Zhang G, Yoshida T, et al. Perturbation of the mutated EGFR interactome identifies vulnerabilities and resistance mechanisms. Mol Syst Biol 2013;9:705.
11. Alves Rde C, Meurer RT, Roehe AV. MYC amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study. J Cancer Res Clin Oncol 2014;140:2021-5.
12. Luk KC, Simcox ME, Schutt A, Rowan K, Thompson T, Chen Y, et al. A new series of potent oxindole inhibitors of CDK2. Bioorg Med Chem Lett 2004;14:913-7.
13. Davis PD, Hill CH, Lawton G, Nixon JS, Wilkinson SE, Hurst SA, et al. Inhibitors of protein kinase C.1. 2, 3-Bisarylmaleimides. J Med Chem 1992;35:177-84.
14. Patricelli MP, Szardenings AK, Liyanage M, Nomanbhoy TK, Wu M, Weissig H, et al. Functional interrogation of the kinome using nucleotide acyl phosphates. Biochemistry 2007;46:350-8.
15. Hook KE, Garza SJ, Lira ME, Ching KA, Lee NV, Cao J, et al. An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735. Mol Cancer Ther 2012;11:710-9.
16. Sos ML, Dietlein F, Peifer M, Schottle J, Balke-Want H, Muller C, et al. A framework for identificationof actionable cancer genome dependencies in small cell lung cancer. Proc Natl Acad Sci U S A 2012;109:17034-9.
17. Ou YH, Torres M, Ram R, Formstecher E, Roland C, Cheng T, et al. TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation. Mol Cell 2011;41:458-70.
18. Deng T, Liu JC, Chung PE, Uehling D, Aman A, Joseph B, et al. shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. Cancer Res 2014;74:2119-30.
19. Kim JY, Welsh EA, Oguz U, Fang B, Bai Y, Kinose F, et al. Dissection of TBK1 signaling via phosphoproteomics in lung cancer cells. Proc Natl Acad Sci U S A 2013;110:12414-9.
20. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001;411:355-65.
21. Zhou J, Chen Z, Malysa A, Li X, Oliveira P, Zhang Y, et al. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy. PLoS One 2013;8:e58091.
22. Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome. Breast Cancer Res Treat 2010;122:347-57.
23. Bhola NE, Jansen VM, Bafna S, Giltnane JM, Balko JM, Estrada MV, et al. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer. Cancer Res 2015;75:405-14.
24. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005;7:591-600.
25. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
26. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
27. Wildey G, Chen Y, Lent I, Stetson L, Pink J, Barnholtz-Sloan JS, et al. Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer. PLoS One 2014;9:e106784.
28. Lemeer S, Zorgiebel C, Ruprecht B, Kohl K, Kuster B. Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. J Proteome Res 2013;12:1723-31.
29. Kunz RC, McAllister FE, Rush J, Gygi SP. A high-throughput, multiplexed kinase assay using a benchtop orbitrap mass spectrometer to investigate the effect of kinase inhibitors on kinase signaling pathways. Anal Chem 2012;84:6233-9.
30. Fang B, Hoffman MA, Mirza AS, Mishall KM, Li J, Peterman SM, et al. Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides. Methods 2015;81:41-9.
31. Kettenbach AN, Schweppe DK, Faherty BK, Pechenick D, Pletnev AA, Gerber SA. Quantitative phosphoproteomics identifies substrates and functional modules of Aurora and Polo-like kinase activities in mitotic cells. Sci Signal 2011;4:rs5.